Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP735975.RA1Om1X_bge5bJdXCm_mZnxnv_E2bJ12s-JtRuuRmRnFs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP735975.RA1Om1X_bge5bJdXCm_mZnxnv_E2bJ12s-JtRuuRmRnFs130_assertion type Assertion NP735975.RA1Om1X_bge5bJdXCm_mZnxnv_E2bJ12s-JtRuuRmRnFs130_head.
- NP735975.RA1Om1X_bge5bJdXCm_mZnxnv_E2bJ12s-JtRuuRmRnFs130_assertion description "[Taken together with similar recent studies of neuroblastoma- and glioblastoma-derived cells, PI3K inhibition seems to be a more general option to sensitize tumor cells to anthracyclines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP735975.RA1Om1X_bge5bJdXCm_mZnxnv_E2bJ12s-JtRuuRmRnFs130_provenance.
- NP735975.RA1Om1X_bge5bJdXCm_mZnxnv_E2bJ12s-JtRuuRmRnFs130_assertion evidence source_evidence_literature NP735975.RA1Om1X_bge5bJdXCm_mZnxnv_E2bJ12s-JtRuuRmRnFs130_provenance.
- NP735975.RA1Om1X_bge5bJdXCm_mZnxnv_E2bJ12s-JtRuuRmRnFs130_assertion SIO_000772 23300809 NP735975.RA1Om1X_bge5bJdXCm_mZnxnv_E2bJ12s-JtRuuRmRnFs130_provenance.
- NP735975.RA1Om1X_bge5bJdXCm_mZnxnv_E2bJ12s-JtRuuRmRnFs130_assertion wasDerivedFrom befree-20140225 NP735975.RA1Om1X_bge5bJdXCm_mZnxnv_E2bJ12s-JtRuuRmRnFs130_provenance.
- NP735975.RA1Om1X_bge5bJdXCm_mZnxnv_E2bJ12s-JtRuuRmRnFs130_assertion wasGeneratedBy ECO_0000203 NP735975.RA1Om1X_bge5bJdXCm_mZnxnv_E2bJ12s-JtRuuRmRnFs130_provenance.